<code id='14FA937BF4'></code><style id='14FA937BF4'></style>
    • <acronym id='14FA937BF4'></acronym>
      <center id='14FA937BF4'><center id='14FA937BF4'><tfoot id='14FA937BF4'></tfoot></center><abbr id='14FA937BF4'><dir id='14FA937BF4'><tfoot id='14FA937BF4'></tfoot><noframes id='14FA937BF4'>

    • <optgroup id='14FA937BF4'><strike id='14FA937BF4'><sup id='14FA937BF4'></sup></strike><code id='14FA937BF4'></code></optgroup>
        1. <b id='14FA937BF4'><label id='14FA937BF4'><select id='14FA937BF4'><dt id='14FA937BF4'><span id='14FA937BF4'></span></dt></select></label></b><u id='14FA937BF4'></u>
          <i id='14FA937BF4'><strike id='14FA937BF4'><tt id='14FA937BF4'><pre id='14FA937BF4'></pre></tt></strike></i>

          
          WSS
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion